The estimated Net Worth of Leslie Holsinger is at least $652 Тысяча dollars as of 11 December 2020. Dr Holsinger owns over 40,000 units of Cortexyme Inc stock worth over $84,825 and over the last 5 years he sold CRTX stock worth over $0. In addition, he makes $567,000 as Exec. VP of R&D at Cortexyme Inc.
Dr has made over 2 trades of the Cortexyme Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 40,000 units of CRTX stock worth $10,800 on 11 December 2020.
The largest trade he's ever made was exercising 40,000 units of Cortexyme Inc stock on 11 December 2020 worth over $10,800. On average, Dr trades about 6,214 units every 0 days since 2020. As of 11 December 2020 he still owns at least 43,500 units of Cortexyme Inc stock.
You can see the complete history of Dr Holsinger stock trades at the bottom of the page.
Dr. Leslie J. Holsinger Ph.D. is the Exec. VP of R&D at Cortexyme Inc.
As the Exec. VP of R&D of Cortexyme Inc, the total compensation of Dr D at Cortexyme Inc is $567,000. There are 5 executives at Cortexyme Inc getting paid more, with Michael Detke having the highest compensation of $1,100,170.
Dr D is 56, he's been the Exec. VP of R&D of Cortexyme Inc since . There are 5 older and 13 younger executives at Cortexyme Inc. The oldest executive at Cortexyme Inc is Una Ryan, 78, who is the Lead Independent Director.
Leslie's mailing address filed with the SEC is C/O CORTEXYME, INC., 269 EAST GRAND AVE., SOUTH SAN FRANCISCO, CA, 94080.
Over the last 21 years, insiders at Cortexyme Inc have traded over $59,595,534 worth of Cortexyme Inc stock and bought 19,273,711 units worth $164,053,955 . The most active insiders traders include & Johnson Johnson & Johnson..., Farmaceutici Sp A Chiesi и Ansbert Gadicke. On average, Cortexyme Inc executives and independent directors trade stock every 59 days with the average trade being worth of $475,426. The most recent stock trade was executed by Caryn Gordon Mc Dowell on 6 June 2022, trading 10,800 units of CRTX stock currently worth $30,888.
Cortexyme, Inc. is a clinical stage biopharmaceutical company pioneering upstream therapeutic approaches designed to improve the lives of patients diagnosed with Alzheimer's and other degenerative diseases. Based upon the evidence generated to date, Cortexyme is currently advancing its lead therapeutic candidate, atuzaginstat (COR388), in the GAIN Trial, an ongoing Phase 2/3 clinical trial in patients with mild to moderate Alzheimer's disease. Cortexyme is targeting a specific, infectious pathogen found in the brain and other organs and tied to degeneration and inflammation in humans and animal models.
Cortexyme Inc executives and other stock owners filed with the SEC include: